Tetracyclines Inhibit Protein Glycation in Experimental Diabetes
| Autor: | N. S. Ramamurthy, L. M. Golub, Maria Emanuel Ryan |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Blood Glucose
Glycation End Products Advanced Male 0301 basic medicine medicine.medical_specialty Glycosylation Tetracycline Streptozocin Diabetes Mellitus Experimental Rats Sprague-Dawley 03 medical and health sciences 0302 clinical medicine Glycation Internal medicine Diabetes mellitus medicine Extracellular Animals Doxycycline Analysis of Variance business.industry 030206 dentistry General Medicine medicine.disease Streptozotocin Rats Rats Zucker 030104 developmental biology Endocrinology Tetracyclines Collagen Hemoglobin business Protein Processing Post-Translational medicine.drug |
| Zdroj: | Advances in Dental Research. 12:152-158 |
| ISSN: | 1544-0737 0895-9374 |
| DOI: | 10.1177/08959374980120011201 |
| Popis: | Glycation of proteins, which is accelerated in the diabetic state, has been implicated in many of the long-term complications of diabetes. This process can be inhibited by members of the tetracycline family of compounds. This novel finding is supported by studies conducted on drug (streptozotocin)induced Type I and genetic (ZDF/Gmi- fa/fa) Type II diabetic rats. These animals were orally gavaged daily with 5 mg of doxycycline and a variety of non-antimicrobial chemically modified tetracycline derivatives for time periods of 3 weeks to 11 months, while control untreated diabetic and nondiabetic animals were gavaged with vehicle alone (2% CMC). Blood and tissue samples were collected and analyzed for glucose and glycated proteins. None of the treatments had any effect on the severity of hyperglycemia or the intracellular glycation of hemoglobin of either Type I or II diabetic animals. However, the tetracycline analogues did affect the extracellular glycation of several proteins such as those found in the serum as well as skin collagen. In the Type II (ZDF) animals, initial mortality (3-5 months) was seen only in the doxycycline-treated animals, associated with infection by tetracycline-resistant micro-organisms, which was eventually surpassed by mortality rates in the untreated diabetics (6-9 months). CMT treatment not only decreased mortality but also increased longevity in the Type II diabetic animals, most likely by preventing the development of a number of long-term complications of uncontrolled diabetes, including glycation of proteins, that eventually lead to the demise of untreated diabetic animals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|